You are here
P&T November 2018
Which ADP receptor inhibitor are patients likely to receive to treat acute coronary syndromes? Although clinical and economic studies lean toward prasugrel and ticagrelor, the authors find that clopidogrel is often prescribed; however, one study shows that the newer agents may be underutilized in some cases.
Patient safety is often put at risk due to inaccurate medication-history details recorded at hospital admission and discharge. A team of pharmacy students and technicians demonstrate how combining their efforts increased the accuracy of medication lists and improved patient care.
The recent approval of angiotensin II (ATII) gives clinicians a new tool for treating patients with septic shock. The drug is highly effective at improving blood pressure in patients with acute respiratory distress syndrome, but its adverse-event profile and cost are cause for concern. This commentary examines the controversies surrounding the safety and efficacy of ATII.
We review sessions on the association of diuretic use and amputations, albiglutide and cardiovascular outcomes with diabetes and cardiovascular disease, how lorcaserin affects diabetes in overweight patients, how testosterone therapy improves diabetes in hypogonadal men, the pros and cons of gastric bypass surgery, how low-calorie sweeteners affect the gut microbiome, and more.
The final part of a 3-part series discusses medication safety risks related to labeling, patient education, and medication storage.
P&T committees may soon have access to more than drug-label information as HHS considers implementing a safe harbor for value-based contracts between drug manufacturers and health insurers.
Approvals, new indications, regulatory activities, and more
Arakoda (tafenoquine) for malaria; Annovera (segesterone acetate and ethinyl estradiol vaginal system) for contraception; and Oxervate (cenegermin-bkbj) for neurotrophic keratitis
Baxdela (delafloxacin) for treatment of acute bacterial skin and skin structure infections